The CDMO will collaborate with Pandorum on its “liquid cornea” product, while providing an exclusive GMP suite for production of Genenta’s cell therapy.
With capacity increasing from six to 12 bioreactors for mammalian cell culture, the CDMO says Hillerød is the largest end-to-end biopharma manufacturing site in Europe.
Boehringer Ingelheim has licensed Synaffix’s antibody-drug conjugate technology, while Samsung is expanding ADC services through a partnership with LigaChem Biosciences.
The San Diego-based CDMO said it made the decision to “right size” its Durham, N.C. facility “based on demand in the gene therapy sector, which requires reducing headcount.”
The CDMO said an undisclosed “non-competitive buyer” purchased the high-speed, multi-purpose filler which was not installed and represented excess capital equipment.
The sale of the Chinese CDMO’s manufacturing site in Ireland comes weeks after WuXi AppTec announced it was selling WuXi Advanced Therapies to a U.S. firm.
Published on Jan. 2, 2025, the document provides updated eligibility criteria and submission guidelines, building on a draft released in December 2023.
The Chaska, Minn.-based company reported an 8% increase in quarterly revenues and installed a high-speed, GMP-ready 5-head isolator filler, doubling its capacity.
Innovent will receive an upfront payment of $80 million and is eligible for up to $1 billion in milestone payments, along with royalties on future sales.
The initial public offering comes as global drugmakers are looking to India, among other countries, to limit their dependence on Chinese contract manufacturers.
Oqory’s lead candidate has demonstrated promising clinical results in treating solid tumors, with a differentiated safety profile compared to other TROP2 ADCs.
This year, the sector saw a record number of U.S. approvals, with high expectations for the clinical pipeline in 2025. But companies like bluebird bio face major hurdles.
The sale of the U.S. and U.K. operations of WuXi Advanced Therapies, WuXi AppTec’s cell and gene therapy manufacturing arm, is for an undisclosed amount.
Under the deal, Akums Drugs & Pharmaceuticals will manufacture select oral liquid formulations to be marketed in multiple European countries by the undisclosed company.
While the two companies dominate the market, Celltrion’s strong presence in deal-making is driving South Korea’s growing influence in the global biosimilars landscape.
Designed to produce 20 billion capsules annually, the new 175,000-square-meter facility leverages technology to enhance product quality and supply chain efficiency.
The regulator on Thursday confirmed that Eli Lilly’s tirzepatide, the active ingredient in Mounjaro for type 2 diabetes and Zepbound for obesity, is not in shortage.
The buyout takes private one of the largest CDMOs. In a separate transaction, Novo Nordisk paid Novo Holdings $11 billion to take over three Catalent fill-finish sites.
The first phase of the company’s Manufacturing Optimization Program will deliver initial net cost savings in the latter part of 2025, executives told analysts on Tuesday.
